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Candida: A Disease of Antibiotics
Initial reporting of penicillin as a wonder drug emphasised the fact that
it was derived from a fungus, and a common one at that. Fungi of the
genus Penicillia are ubiquitous in the soil and rotting matter across the
world. They are most commonly seen in the bluish mould growing
on old fruits and bread, and there are speciﬁc species associated with
types of cheese: P. camemberti and P. roqueforti. Indeed, the species that
Alexander Fleming derived his pioneering antibacterial from agent was
the common P. chrysogenum (formerly P. notatum), that was common
enough in London to blow in through the window of his laboratory.1
The main antibiotics that followed penicillin were also derived from
fungi: streptomycin from Streptomyces griseus, tetracycline from Strepto-
myces rimosus, cephalosporin from Cephalosporium acremonium and, as
discussed in the previous chapter, griseofulvin from Penicillium griseoful-
vum. These discoveries changed the proﬁle of fungi in popular culture,
from agents of contamination and decay to those of medical progress
and human improvement, and there was renewed recognition of their
role in food and drink production.2 Antibiotics affected fungal infec-
tions in medicine in two main ways: ﬁrst, they prompted a search for
antifungal as well as antibacterial agents and second, antibiotics seemed
to open the body to new types of invasive fungal infection, the most
serious of which was with Candida albicans (C. albicans), which was
well known as the cause of thrush or yeast infections.3 Thrush was
commonly seen as an oral infection, especially in babies, and a genital
infection in adults, particularly women.
In medicine, the success of antibiotics in treating bacterial infections
deﬁned what many historians have termed the ‘Therapeutic Revolution’
of the mid-twentieth century.4 The better control of bacterial infections
allowed more ambitious surgical procedures and the pharmaceutical
67
A. Homei et al., Fungal Disease in Britain and the United States 1850–2000
© Aya Homei and Michael Worboys 2013
68 Fungal Disease in Britain and the United States 1850–2000
industry produced drugs for the cure or better management of a seem-
ingly ever growing range of diseases. However, assessments of the impact
of antibiotics nowadays balance the optimism of effective cures for bac-
terial infections, with the increase in the number and seriousness of
antibiotic resistant bacteria.5 In fact, antibiotic resistance was recognised
in the early 1940s and by the early 1950s, streptomycin, which had
radically altered the prospects of tuberculosis sufferers, had to be taken
with two other drugs, isoniazid and para-aminosalicylic acid (PAS), in
part, to overcome antibiotic resistance.6 Less well recognised, and an
important theme of this chapter, is of how antibiotics opened the body
to new types opportunistic infections, with systemic mycoses amongst
the most difﬁcult to manage. Writing in 1955, Ernest Jawetz, a micro-
biologist at the University of California Medical Center, San Francisco,
wrote that that the ‘ “rise of the yeasts” during antibiotic administra-
tion has been noted quite generally’ and that the ‘pathogenic potential
of these fungi has caused concern’.7 At this time the causal organism
was known as Monilia albicans (M. albicans) and the infection monilia-
sis, but this changed to candidiasis or candidosis with the renaming of
the pathogen.8 In this chapter we keep to the terms used by doctors and
others in context; but be warned there were no sudden changes, thus,
old and new terms coexisted for many years.
We begin the chapter with a discussion of thrush in the nineteenth
and early twentieth centuries and its transition from an oral infection
of weak children to a genital infection of women. In both cases, doctors
framed the disease in terms of the metaphor of ‘seed and soil’; namely,
that to spread and develop pathogenic fungi required vulnerable human
tissue, weakened by poor nutrition or other diseases. We then discuss
the ‘Antibiotic Era’ and the inter-connected development of fungi as
sources of antibiotics, including antifungals, and the claims that the use
of antibiotics precipitated a general increase in fungal infections and
new types of systemic fungal disease. The iatrogenic consequences of
antibiotics have been discussed by doctors and historians in relation to
the development of bacterial resistance, but hardly at all with regard to
fungal infections.9 The most prevalent of the new infections was sys-
temic or invasive candidiasis, which was present in new patient groups;
ﬁrstly, patients with leukaemia and those being treated for other can-
cers with steroids; later, transplant patients, and ﬁnally in the 1980s,
people with HIV/AIDS. The common factor was that all were immuno-
compromised or -suppressed, showing once again the importance of the
relationship between bodily ‘soil’ and fungal ‘seeds’. We end the chap-
ter with a discussion of one of the great popular health crazes of the last
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quarter of the twentieth century – ‘The Yeast Connection’ – whose advo-
cates argued that many of the new chronic and debilitating ailments of
modernity were due to C. albicans overgrowth in the body.
Thrush: Weak children
In the mid-nineteenth century, oral thrush was regarded by doctors as
a form of stomatitis, the symptomatic name for inﬂammation of the
mouth, which also included ulcers, bleeding gums and, most seriously,
cranum oris or noma, a gangrenous infection of gums or cheek with tis-
sue destruction. Typically, a thin white membrane covered the palate,
with white spots on the tongue, but in serious cases the tongue, cheeks
and lips were covered, with possible spread to the throat and oesopha-
gus. The condition was most prevalent amongst premature babies and
then at weaning, when food matter stuck to gums and the mouth lining,
acting as both an irritant and medium for infection.10 Local epidemics
were reported in lying-in hospitals, mostly alleged to be spread by poor
hygiene amongst breast feeding mothers. While the disease was typically
short-lived, disappearing as the baby gained weight, in a minority of
cases it spread to the gut or lungs, and death usually followed. Mothers
would say that thrush had ‘gone through’ their children.11
With children, it was an important skill for doctors to be able to diag-
nose differentially thrush from diphtheria; indeed, before the notion of
speciﬁc infections was accepted, doctors believed that the white growth
of thrush often transformed into the membrane of diphtheria as the
child’s health deteriorated.12 The only treatment was to clean the mouth
after meals, irrigate the mouth with glycerine borax and improve the
general diet. Public health doctors saw thrush as a marker of poverty; it
was most common in children with poor dietary and digestive troubles,
which had progressed to general debility and fatigue. Although said to
be common, thrush was rarely discussed in the medical press because
it was either readily treated or self-limiting. However, it was occasion-
ally reported in adult patients in the terminal stages of consumption
and cancer, which resonated with the common observation that fungi
ﬂourished on dying or dead matter.
Thrush: Women and the ‘Whites’
With hindsight, medical mycologists have identiﬁed the ﬁrst publica-
tion on vaginal thrush as being that of Stuart Wilkinson in the Lancet in
1849.13 This article appeared in the context of the contemporary interest
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in fungal theories of disease and was published in the same issue as a
discussion of the alleged cholera fungus.14 Wilkinson wrote that he had
observed ﬁlamentous fungi in discharges from a woman that he traced
to her uterus, but noted the ‘healthiness of the vaginal wall’. Interest-
ingly, today the vaginal wall understood to be the main site of infection,
so it is debatable if this was really the ﬁrst ever case.15 The report stands
alone in nineteenth-century medical literature and there was little or
no direct discussion of fungal infection of the vagina again until the
twentieth century. So, what happened to Wilkinson’s thrush? This is, of
course, the wrong question. What Wilkinson described was not vaginal
thrush in the modern sense of speciﬁc infection, but an instance of ‘leu-
corrhoea’ or ‘the whites’, discharges that doctors deﬁned against ‘red’
menstrual conditions.
Leucorrhoea was difﬁcult terrain for many doctors because it involved
intimate examination of women and was associated with venereal dis-
eases, which might mean difﬁcult questions for patients.16 Speaking in
1862, Grailly Hewitt, one of London’s leading gynaecologists, observed,
[L]et it be remembered that it is impossible for the practitioner to
exercise too great caution in pronouncing an opinion for or against
the speciﬁc nature of a discharge from the female generative organs.
In the words of the late Dr Ashwell, ‘it is always his duty to cure
the disease, but rarely to venture upon an exposition of its nature.
If he can positively afﬁrm that it is of simple origin, let him do so,
if suspicion has been aroused; if not, it is better to avoid any distinct
allusion to the matter.’17
Nineteenth-century medical books on the ‘diseases of women’ dis-
cussed leucorrhoea as a symptom rather than a disease condition in
its own right. White discharges pointed either to constitutional disease,
anything from tuberculosis to hysteria, or to local problems with the
ovaries, fallopian tubes, uterus, cervix or vagina, any of which might be
related to gonorrhoea, syphilis or venereal disease. The doctor’s prime
task was differential diagnosis, prognosis and treatment. If local treat-
ment was recommended, it tended to be the use of anti-inﬂammatories
or ‘milder’ antiseptics, such as mercury, boric acid, permanganate of
potash or silver nitrate.
The direct association of leucorrhoea and speciﬁc fungal infection was
ﬁrst made in 1931 by Everett Plass, Henry Hesseltine and Irving Borts,
obstetricians and gynaecologists from Iowa, who identiﬁed a condition
they termed ‘Monilial vulvovaginitis’.18 Their ﬁnding emerged from a
Candida: A Disease of Antibiotics 71
study of vaginal discharge in two pregnant women, where gonorrhoea
was ﬁrst suspected as the cause, but all tests had proved negative.19
The broader context for this work was the venereal disease services
that were developed after the First World War, through which venere-
ologists became more interested in conditions other than syphilis and
gonorrhoea, especially non-gonococcal urethritis (NGU).20 NGU was an
interesting condition, its diagnosis combined clinical and laboratory
methods and it was essentially deﬁned by what it was not: persistent
genital discharge from which gonococci were absent.21 NGU was almost
exclusively reported in men, with very few women acknowledged suf-
fering similar symptoms due to inﬂammation of the urethra, vagina
or cervix.22 However, in women the principal infective agent found in
cases of leucorrhoea and vaginitis was Trichmonas vaginalis, a protozoan
that seemed to be more prevalent in the United States than Europe, and
C. albicans.23
The other important context was Rhoda Benham’s work on Monilia
fungi and disease.24 Benham worked at the Columbia-Presbyterian Med-
ical Center, where she and her colleagues became leaders in the ﬁeld
of medical mycology in the United States.25 In a paper in the Journal of
Infectious Diseases in September 1931, she argued that M. albicans was a
‘well deﬁned species which can be recognized and differentiated from
related forms by its morphologic and cultural characteristics’ and that
many other organisms, previously regarded as distinct, were in fact the
same species.26 She stated the case directly:
The evidence brought out by the different methods of study of this
group of organisms gave remarkably concordant results. The strains
isolated from thrush, whether called Monilia or Endomyces, the strains
called M. psilosis, isolated from sprue, and the strains from erosion
inter-digitalis, mycotic paronychia, mycotic intertrigo, perleche and
superﬁcial glossitis all showed essentially the same morphology, the
same fermentations, essentially the same antigenic properties, both
on direct agglutination and on absorption of agglutinins, and the
same pathogenicity for rabbits. If one were ignorant of the source
of these cultures, one would be unable to distinguish, for example,
M. albicans isolated from thrush from M. psilosis isolated from sprue,
and it would seem necessary for the present to regard such forms as
merely strains of one species.27
In the following year, she published a short paper in the American Jour-
nal of Public Health, again emphasising that M. albicans was the main
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pathogenic ‘yeast’ found in humans.28 She showed that the Monilia
infecting plants and animals were distinct, and suggested keeping the
term Monilia that for the plant pathogens and adopting Berkhout’s term,
Candida spp., for human pathogens.29 Many mycologists thought the
term Candida albicans unsatisfactory because it literally meant ‘whiten-
ing, white’. Writing in 1940 from Duke University School of Medicine,
Donald Martin and Claudius Jones quoted a French study that had
identiﬁed 102 synonyms for C. albicans, while an Italian review had
listed 121, with only 51 overlapping!30 In 1935, Benham wrote what
turned out to be a forward-looking chapter on ‘Monilia and moniliasis’
in Frederick Gay’s encyclopaedic Agents of Disease and Host Resistance.31
She stressed the role of the Monilia spp. in the following: occasional
epidemics of oral thrush and in association with gingivitis; some skin
lesions and allergic reactions; infections of the vaginal mucous mem-
brane and of the penis; infection of the eyes of the newborn; some
bronchial and pulmonary infections; and generalised disease, often
affecting the brain.
Thrush: Mothers and babies
Gynaecologists and obstetricians also took more interest in fungal
infections in the 1930s, especially in pregnant women, in whom hor-
monal changes were reported to increase susceptibility.32 In 1937 Brooke
Bland and Abraham Rakoff of Jefferson Medical College, Philadelphia
described a study in which 12 pregnant women and 12 non-pregnant
women were infected with C. albicans. As we might expect for the time,
there is no evidence that informed consent was sought or given; though
as a minor, mostly self-limiting infection, doctors would have judged
any danger to patients as negligible and justiﬁable for the progress of
medicine. They found that ten out of 12 pregnant women acquired the
infection, against four who were not pregnant.33 This experiment was
followed up by infecting a further 38 pregnant women, 25 of whom
developed disease. Thrush was also reported to be common in diabetics,
who had the new status of being maintained with insulin injections.34
One idea was that high glucose levels in the blood could precipitate
infection, another was that poor peripheral circulation and changes in
pH predisposed diabetics.35 Thrush was one of the many infections that
made the new diabetes ‘a disease of complications’.36
In the late 1930s, doctors noted that thrush in newborn babies
(neonates) was likely caught from mothers during parturition, and there
was cross-infection across sites in the body.37 In 1940 Glen Liston and
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Lewis Cruickshank published two studies of leucorrhoea in 200 pregnant
women in Edinburgh that showed 49 (25%) had C. albicans infec-
tion, as against 75 with Trichomonas and four with gonorrhoea.38 Their
work was discussed in the Lancet, in an editorial on ‘Vaginal Discharge’
in September 1940 that pointed to personal and social issues for the
patient.39
One of the most distressing complaints that the gynaecologist and
general practitioner are called on to treat is vaginal discharge. To
the patient it is demoralising, because of its intractability, and in a
sensitive woman it may cause considerable mental trauma. To the
layman, moreover, a vaginal discharge carries a sinister innuendo –
many an innocent woman has suffered unmerited blame from hus-
band or family for a non-venereal infection, and a discharge has even
been the starting point of an action for divorce.40
The importance of differential diagnosis, of what was also termed ‘vagi-
nal mycosis’, was emphasised, along with the new possibilities for
treatment.
The Lancet editorial was followed up by three letters. Dr Mary Michael-
Shaw of the Royal Free Hospital and Salvation Army Mothers’ Hospital
in London recommended using specialist laboratories for diagnosis.
Along with the other correspondents, she discussed treatment and rec-
ommended Stovarsol (branded as Spirocid and Arsetosone), an arsenical
originally produced in the Ehrlich’s series that gave the world Salvarsan.
Stovarsol was No. 594 and sometimes recommended for syphilis.41
In his letter, Lewis Cruickshank recommended ‘bi-weekly painting of
the whole vagina, external genitalia, thighs and pubic region with 2%
aqueous gentian violet’, while other doctors described their successful
treatments with antibacterial douches, using products such as Eli Lilly’s
Negatan (also called Negatol) and Monsol.42 Drug companies, increas-
ingly aware of the new market created by thrush infections, developed
new formulations and carriers for topical antiseptics, such as gentian
violet, marketed as ‘gentia-jel’.
The accepted ‘reference’ study of neonatal oral thrush in Britain as an
emerging problem was published in 1942 by two bacteriologists from
Edinburgh, G. B. Ludlam and J. L. Henderson.43 It was based on a survey
of babies born at the Royal Inﬁrmary in the city in 1940. The inci-
dence of the condition diagnosed clinically was 6.4% (163 cases) in that
year, down from 7.2% (168 cases) in the previous year, but the ﬁgure
was believed to be higher, as many babies only showed symptoms after
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discharge. A group of ‘60 unselected infants’ was tested by swabbing and
laboratory testing, which revealed the fungus in 18.3% (11 cases), almost
three times that diagnosed symptomatically. The authors suggested that
the difference pointed to a signiﬁcant level of latent disease, or benign
presence of the fungus. Amongst babies with symptoms, the incidence
was highest in premature babies, then in those partly or wholly bottle-
fed, and lowest in those breast-fed. There was seemingly no discussion
over whether thrush was increasing because of the rise in the number
of hospital births, or the switch from breast to bottle feeding that was
being reported in the 1940s.44
Paediatricians showed more interest in Candida infection as a poten-
tially serious condition and warned that it could rapidly change from
trivial to life threatening. If it spread to the oesophagus, stomach and
intestines, symptoms were diffuse and often missed, with Candida infec-
tion often only recognised at post mortem.45 Such concerns added to
the uncertainties about the nature and management of thrush. On the
one hand, it appeared to be very common and in the great majority of
cases cleared up quickly, but on the other hand it might be a sign of
poor general health or a warning of very serious underlying disease.46
In succeeding years the clinical picture worsened further with claims
that Candida infection could also spread to the lungs and even develop
as systemic disease, similar to septicaemia.47
In 1952, Ian Donald, later a pioneer of ultrasound in obstetrics, then a
Reader in obstetrics at the University of London, published on the infec-
tions seen at the Institute of Obstetrics and Gynaecology’s ‘D’ Clinic
in London over the previous ﬁve years.48 The breakdown of the cause
of infections in women, after gonorrhoea had been excluded, was Tri-
chomonas vaginitis (TV) – 37.4%; Monilia – 16.2%, TV and Monilia –
7.7%; – miscellaneous 33.5%, and – ‘insufﬁcient information’ 5.1%.
The following year, in a series of ‘Refresher Courses for General Prac-
titioners’, Scott Russell, Professor of Obstetrics and Gynaecology at the
University of Shefﬁeld, recommended rigorous cleansing and disinfec-
tion of the vagina before childbirth to ﬂush out Candida and other
pathogens.49 There were critics who maintained that such measures
made infection more likely, causing irritation and inﬂammation. They
also argued that it was better to encourage the normal micro-ﬂora of the
body, which helped make the bodily soil less vulnerable to infection.
Doctors also speculated that new clothing fashions and materials, such
as tight-ﬁtting nylon underwear that kept the skin warm and moist,
had contributed to the increase in the incidence of thrush in women.50
It was not without irony then that the most talked about underwear
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of the 1950s, though only seen in newspaper photographs and not by
movie theatregoers, were the panties worn by Marilyn Monroe when
she stepped into the updraft from the subway grate in the movie ‘The
Seven Year Itch’.51
Yeasts and ‘the antibiotic era’
In June 1951, the Council on Pharmacy and Chemistry of the American
Medical Association (AMA) agreed that a statement should be printed on
bottles of three leading antibiotics (aureomycin, chloramphenicol and
terramycin) to warn ‘that patients receiving these drugs may be more
susceptible to ‘Monilial or other yeast-like organisms’.52 This initiative
was made in the context of patients showing all manner of adverse reac-
tions to the new antibiotics. From the ﬁrst use of penicillin, there had
been many, many celebratory assessments of lives saved and improved
by the new ‘wonder drugs’, but by the early 1950s these celebrations
had been tempered. Concerns were expressed by doctors and the pub-
lic about antibiotic use on several fronts: resistance in certain bacteria;
allergic reactions in patients, including anaphylactic shock; and a grow-
ing incidence of superﬁcial and invasive fungal infections.53 In 1951, a
collection of essays was published entitled Penicillin Decade 1941–1951:
Sensitizations and toxicities.54 Some of the most prominent side effects
were noticed on the skin, in the form of rashes, and in the mouth,
with inﬂammation and infection of various types, including C. albi-
cans growth.55 What attracted most attention was the development of
so-called ‘superinfections’, as when Staphylococcus aureus colonised tis-
sues from which other bacteria had been cleared by broad-spectrum
antibiotics. Previously, doctors had used the term to refer to a secondary
infection of the same pathogen, especially in cases of syphilis and tuber-
culosis, but in the 1950s the ‘super’ came largely to refer to secondary
infections of a different pathogen and, in the case of secondary mycotic
infections, the term ‘fungal overgrowth’ was coined.56
It is often forgotten that until the mid-1950s penicillin and other
antibiotics were largely administered by injection or used topically,
because the formulations available were poorly absorbed by the gut.57
For external infections, penicillin was administered in creams and other
carriers, including mouthwashes and pessaries, while aerosols were
developed for throat and bronchial infections.58 For most serious infec-
tions, penicillin was given by injection into muscles or via saline drip,
which meant that it was most readily given to hospital patients. Gen-
eral practitioners were required to make three or four home visits each
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day to give injections to keep up the levels of the antibiotic in the
system.
The awareness of the adverse effects of antibiotics grew with the
arrival in the late 1940s of tetracycline, which was both broad spec-
trum and taken orally, and could cause the yellowing of teeth in infants
and photosensitivity. Initially, fungal overgrowth was well down the list
of concerns, top of which were allergic and toxic reactions, vitamin
deﬁciency, the development of resistance and bacterial overgrowth.59
Indeed, many reviewers implied that the extent and seriousness of fun-
gal overgrowth had been overstated by medical mycologists talking up
the importance of their specialism. The ﬁrst clinical discussion of fungal
overgrowth was in June 1949, when Harold Harris spoke at the New York
Academy of Medicine on treating patients suffering from brucellosis
with aureomycin and chloramphenicol.60 He suggested that overgrowth
was due to a combination of C. albicans gaining virulence in the absence
of bacterial competition, the destruction of intestinal bacterial ﬂora, and
the lowering of the vitality of gut tissues. He worried too about the per-
manence of the changes and the development of more virulent strains of
the fungus. In June 1951, James Woods and colleagues, from the Watts
and McPherson Hospitals in Durham, North Carolina, published a study
of 25 patients who had developed C. albicans infection after treatment
with various antibiotics.61 The study found no evidence that antibiotics
had a stimulating effect of the fungus, but conﬁrmed the view that the
removal of competing bacteria cleared the gut for fungal colonisation.
The report also suggested that treatment with vitamin B complex offered
some amelioration, but could give no reason why, other than perhaps
it improved the general nutritional status of the body. However, the
immediate reason for the intervention of the Council on Pharmacy and
Chemistry in June 1951 was because of reports that aureomycin, chlo-
ramphenicol and terramycin could precipitate fungal infection of the
lungs, whereas the bowel infections noted previously had been ‘of little
consequence’.
Cases of broncho-pulmonary moniliasis had been reported in medi-
cal journals for decades.62 The increased attention given to tuberculosis
after the Second World War, because of mass X-ray screening and effec-
tive antibiotic treatment, revealed a greater prevalence of broncho and
pulmonary mycotic disease.63 A study by Robert Oblath and colleagues
in California, published in July 1951, argued that C. albicans should
be added to the list of mycotic pulmonary organisms alongside Coccid-
ioides immitis and Histoplasma capsulatum, which we discuss in the next
Chapter.64 There were also reports of C. albicans infection of the heart
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(endocarditis) and kidneys. This gave wider recognition to the possibil-
ity that moniliasis was changing from an irritating, though relatively
mild disease of mucous membranes in the mouth and genitalia, to a
serious, often fatal disease of major internal organs. An editorial in the
British Medical Journal in June 1951 noted the decision of the Council
of Pharmacy and Chemistry, but was sceptical of the need for a similar
warning about tetracycline in Britain. 65 The writer suggested that ‘there
was much more extensive use of these drugs generally in America’ and
that it had brought to light complications which were unfamiliar to
doctors in Britain.
A year after the call for warnings on tetracycline packaging, an edito-
rial in JAMA reafﬁrmed the action and concluded that ‘The occurrence
of moniliasis as a complication of antibiotic therapy has been deﬁnitely
established.’66 This claim was contested by Albert Kligman, whose work
was discussed in Chapter 2.67 Kligman argued that, with respect to the
impact of wide-spectrum antibiotics, the ‘incrimination of moniliasis as
the cause of numerous side-reactions requires critical reappraisal’. He
advanced four points. Firstly, much of the evidence for the enhance-
ment of fungal growth came only from in vitro experiments.68 Secondly,
he suggested that ‘reported instances of localized moniliasis are not actu-
ally cases of this disease’, but rather instances of inﬂammation due to
many causes, where C. albicans, a common non-pathogenic presence
in many part of the body, might be expected to be found.69 Thirdly,
he argued that diagnoses had been made on insufﬁcient evidence and,
fourthly, that mycotic diseases had complex aetiologies, where a single
factor, such as the presence of an antibiotic, was unlikely to be sufﬁcient
to produce disease. Kligman ended by warning that the development
of antibiotic resistance in staphylococcal and streptococcal bacteria
‘is likely to be of far greater signiﬁcance than the problem of super-
infections with fungi’.70 Ernest Jawetz complained that Kligman was
minimising the dangers of moniliasis, saying that ‘the overgrowth of
yeasts was mainly a saprophytic surface phenomenon’.71
However, Kligman’s views were supported by clinical assessments
in the mid-1950s. Louis Weinstein and Lois Finland, writing in the
New England Journal of Medicine in February 1953 on ‘Complica-
tions induced by antimicrobial agents’, mentioned fungal infection
very brieﬂy and focused on hypersensitivity and superinfections from
antibiotic-resistant bacteria.72 In a paper the following year, Weinstein
announced his ﬁndings on 3015 patients treated with antibiotics, where
52 or 1.74% developed superinfections, of which only seven were due
to C. albicans.73 In a study published in the Lancet in 1954, Jessie Sharp
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reported that the incidence of C. albicans in the throat, sputum and rec-
tum of patients had doubled during oxytetracycline therapy. However,
presence of the fungi was not necessarily associated with disease and the
only concern expressed was that these patients would spread C. albicans
at home when discharged.74
Despite the relatively low case incidence, antibiotic induced mon-
iliasis (or as it was increasing referred to candidosis or candidiasis)
attracted interest, not least because doctors linked it to the new phe-
nomenon of systemic Candida infection in patients who were severely
debilitated or immunocompromised from other diseases, or receiving
toxic treatments for leukaemia, such as nitrogen mustard therapy.75 The
general point made by medical mycologists was that recent innovations
were changing the internal milieu of the body to achieve radical ther-
apeutic advances, but that this led to C. albicans emerging as a serious
pathogen because it was already present in the healthy body, usually
harmless or perhaps even in a symbiotic relationship.76
Nystatin – The ﬁrst antifungal antibiotic
The narrative of the antifungal drugs in the antibiotic era is dominated
by the discovery of nystatin by Elizabeth L. Hazen and Rachel F. Brown
at the Albany Laboratory of the New York State Department of Health.
Their story has been told in Richard Baldwin’s book The Fungus Fight-
ers: Two Women Scientists and Their Discovery.77 Hazen had worked as a
bacteriologist since 1931 and took the special course in medical mycol-
ogy at the College of Physicians and Surgeons of New York, befriending
Rhoda Benham. Brown was an organic chemist who had joined the
Albany Laboratory in 1926 and worked on serum diagnoses, including
the Wassermann Reaction for syphilis. They began to work together to
try to ﬁnd antifungal agents against Coccidioides and Candida, and in
the fashion of the time turned to the soil and the chemicals produced
by fungi.78 Within two years, in a soil sample from a friend’s garden,
they found that the fungus Streptomyces noursei had yielded an antifun-
gal compound, which they called fungicidin. It was both fungistatic –
preventing the multiplication of organisms – and fungicidal – actually
killing organisms.79 The discovery was announced at a regional meeting
of the National Academy of Science in October 1950.80
Two years later, Selman Waksman, who was then Professor of Microbi-
ology at Rutgers University, New York and soon to accept the 1952 Nobel
Prize in Physiology and Medicine for the development of streptomycin,
bemoaned the fact that screening of new chemotherapeutic agents
had been mostly for antibacterial, rather than antifungal activity.81 He
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argued that there was no a priori reason why fungi had not developed
antagonistic reactions to other fungi as well as bacteria. Indeed, both
penicillin and tetracycline had proved effective in the treatment of acti-
nomycosis, then classiﬁed as a fungal disease.82 Waksman suggested
that, as there were many effective topical antifungals, the research ‘prize’
would go to anyone ﬁnding an antifungal that could be injected, or
taken orally to attack topical infections from within and combat the
emerging problem of systemic infections. He pointed out that such
chemicals would also be very useful in veterinary medicine, where fun-
gal diseases were found to be endemic and often epidemic. Waksman
identiﬁed the actinomycetes as the most promising group for antifun-
gals and particularly Streptomyces spp., the potential of which had been
demonstrated by Hazen and Brown. However, he was only able to report
promisingly fungistatic and fungicidal results in laboratory studies.
Nystatin was introduced as ‘Mycostatin’ in 1954. Finance for its devel-
opment came from a private foundation, the Research Corporation for
Scientiﬁc Advancement (RCSA). This organisation, which had been cre-
ated in 1912, received and distributed funds for what would now be
termed near-market research and with nystatin the RCSA dealt with
patents, licences and development. The drug was produced under an
agreement, between E. R. Squibb and Sons, the RCSA, and Hazen and
Brown, which saw part of the income from sales and royalties reinvested
in research by the RCSA and in the newly created Brown-Hazen Fund.
An indication of the success of nystatin was that by 1960, income to the
fund had risen to $200,000, which was used mainly to support training
programmes in medical mycology.83
Squibb issued Mycostatin in powder form, which doctors and phar-
macists made up into ointments, lotions, pessaries and sprays with
appropriate carriers.84 However, it was soon available in tablets for oral
administration to treat intestinal moniliasis where non-absorption was
a boon as the compound remained at high levels in the gut.85 It was
marketed for the treatment of three conditions: oral thrush, vaginal
thrush and ‘monilial overgrowth’ in the intestines. Doctors reported
good results, and in topical applications patients welcomed not having
to suffer the indignity of having their mouths and other parts painted
with gentian violet.86 There were no reported side effects from the top-
ical application of nystatin, but when doctors tried injecting the drug
there were problems: pain at the site of injection; then shaking, chills,
fever and general malaise, and some long-term effects, such as sclerosing
of the veins. Nystatin prompted the ﬁrst international symposium on
fungal therapy in Los Angeles in June 1955, where one question, perhaps
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surprisingly given the proﬁle of nystatin, was: Why is topical therapy
for the superﬁcial mycoses so ineffective?87 In all, there were 56 papers
on every possible aspect of the topic, as the contents page revealed:
‘therapy, epidemiology, biology, ecology, reservoir pathogenicity, and
immunization in fungus diseases, a number of factors bearing indirectly
on therapy, such as laboratory controls and hormonal inﬂuences’.88 Nys-
tatin was more effective than previously available compounds, but it was
not a cure-all in the clinic.
The ﬁrst British clinical report of the use of nystatin for vaginal thrush
was in March 1955. Two women who had suffered for many months
and endured the irritation, inconvenience and often the embarrassment
of using gentian violet, enjoyed rapid symptomatic relief with nys-
tatin pessaries.89 The following March, two general articles on nystatin
were published in the British Medical Journal, which prompted letters on
local experience in Oxford and London.90 In September 1956, details of
larger clinical trials began to appear. Harry Pace and Samuel Schantz,
from Brooklyn, presented details of 59 patients with laboratory con-
ﬁrmed C. albicans vaginitis that were treated simply by the insertion
of nystatin tablets into the vagina. The average success rate was 98.3%:
100% amongst the 31 women who were pregnant and 96.3% in the
non-pregnant.91 A similar study by Warren Lang and colleagues at the
Jefferson Hospital, Philadelphia, with 70 patients, again showed prompt
symptomatic relief and near total success.92 However, other reports were
more mixed; for example, one study from Los Angeles published in 1957
showed ‘excellent’ results in 43% of patients, ‘good’ results in 53% and
fair results in 4%.93
Trials in Britain were similar. In January 1957, Roy Jennison and
J. D. Llywelyn-Jones at St Mary’s Maternity Hospital, Manchester,
reported 88% success with nystatin in cases of thrush, compared to 47%
with gentian violet. Later that year, William Barr, at the Western Inﬁr-
mary in Glasgow, published his trials with 64 women: 55 (86%) were
‘completely cured’ (mycologically clear); 62 (97%) were cured symp-
tomatically; and only 10 (16%) relapsed.94 He also gave the outcomes
of 12 diabetic women with infection, where results were less positive:
nine (75%) were cured symptomatically, but two of these had relapsed.
Barr linked this to raised levels of sugar in the urine that provided a
substrate for the fungi to develop.
In the 1950s, the most controversial use of nystatin was for intestinal
Candida overgrowth in patients taking tetracyclines. In fact, the initial
promotion of ‘Mycostatin’ had suggested its use in the ‘prevention and
treatment of intestinal moniliasis, or candidiasis, especially for patients
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taking oral antibacterial antibiotics for prolonged periods’.95 Many stud-
ies had shown that after taking oral antibiotics, particularly for long
periods, the number of patients with C. albicans in their faeces rose
dramatically.96 There were contrary views about what this meant. Some
doctors argued that it caused diarrhoea and intestinal conditions; others
suggested that most patients with positive rectal swabs had ‘no com-
plaints of diarrhoea, burning sensation on defecation, or soreness of the
anus and surrounding skin’.97
One solution to the alleged problem of Candida overgrowth in the
gut was to give patients on antibiotic regimes nystatin as a prophylac-
tic. Andrew Childs at Ruchill Hospital, Glasgow, trialled this protocol
in 1954 and in 1955 Squibb introduced ‘Mysteclin’, a combination of
tetracycline and nystatin.98 Squibb’s advertising claimed that ‘Myste-
clin’ was valuable for ‘many common infections’, including bronchitis,
meningitis, pneumonia and tonsillitis, and by halting the overgrowth of
C. albicans, it would also protect against ‘gastrointestinal distress, anal
pruritis, vaginitis, and thrush’, any of which on occasion ‘may have
serious and even fatal consequences’. Such drug combinations worried
those doctors concerned about the development of bacterial resistance
and other complications of antibiotic therapy, and they were unhappy
that the drug tacitly accepted the theory of antibiotic-induced fungal
overgrowth.99
In the 1960s ‘Mysteclin’ became controversial in the new context
of drug regulation. It was one of the antibiotic combinations that
prompted an investigation, sponsored by the National Academy of Sci-
ences and National Research Council, into ﬁxed drug combinations in
1969.100 Such drugs were seen by many physicians as ‘irrational’ and
typical of the ‘avaricious marketing’ of pharmaceutical companies, but
others worried at the impact of regulations.101 In the event, ‘Myste-
clin’ was banned by the FDA.102 Squibb started a counter offensive.
This gained notoriety when it emerged that the company had facili-
tated the writing of letters from physicians asking for the ban to be
lifted and enrolled the heads of Harvard and Yale Medical Schools,
who were also paid consultants to the company, to give evidence.103
Squibb came up with a new combination, ‘Mysteclin-F’, in which nys-
tatin was replaced by amphotericin B; the original formulation became
‘Mysteclin-V’.104
By this time amphotericin B was a well known and widely used for
systemic fungal infections. It had been isolated, like nystatin from a
Streptomyces species (S. nodosus), in an antibiotic screening programme
at the Squibb Institute for Medical Research in 1953.105 Puriﬁcation
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produced two compounds: amphotericin A and amphotericin B, and
the latter was shown to counter systemic mycoses in experimentally
infected mice and rats, and to do so through oral administration.
Amphotericin B was licensed in 1955.106 For a while, amphotericin B
promised to be the penicillin of internal fungal infections, but its clini-
cal use proved problematic. The compound was not readily absorbed by
the gut, though Squibb overcame this setback by producing a suspen-
sion that could be given intravenously. It was tried with some success
against localised and systemic cryptococcosis, blastomycosis, histoplas-
mosis and coccidioidomycosis, but the side effects were many, severe
and potentially fatal.107 Reactions included fever, and nausea and vomit-
ing, and serious kidney damage. However, the drug was used in patients
with life-threatening systemic fungal infections in what was sometimes
called salvage therapy, with doctors and families calculating that the
chance of a cure was worth the risks.
By the 1960s the two most common types of Candida infection, oral
and vaginal thrush, were well understood by doctors, not least because
the availability and success of nystatin had prompted greater medical
interest. Oral thrush was readily diagnosed by the characteristic white
patches and, if necessary, samples for microscopy and culturing were
easily obtained. In neonates doctors found that infection was mostly
caught from nurses and mothers; in Britain the incidence of Candida
infection in pregnant women was around 15%.108 However, diagnoses
were a problem because of the problematic position of medical mycol-
ogy. Rosalinde Hurley, who then held a joint clinical and microbiology
post at Queen Charlotte’s Maternity Hospital, London, pointed to a ten-
sion between laboratory-based, ‘botany types’ and clinic-based, ‘medical
types’ in the specialism.
A ridiculous situation had in the past been reached in clinical micro-
biology in which the microbiologist believed Candidal vaginitis to
be a clinical diagnosis and the clinician believed it to be a mycolog-
ical diagnosis. The two groups rarely seemed to have discussed the
problem. The situation had now improved, if only to the point of
admitting that a problem existed.109
It seems that the arrival of nystatin, with its broad-spectrum activity,
meant that medical interest in the actual fungi producing infection,
which had never been high, remained cursory.
The success of nystatin also led pharmaceutical and disinfectant com-
panies to introduce products with, allegedly, similar properties, such as
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‘Sporotacin’, candidicin, pimaracine and hamycin.110 There is no doubt
that self-treatment with the new topicals was widely practised. New
prescription antifungals continued to be launched by pharmaceutical
companies, including topical amphotericin B, with claims of 85–95%
cure rates, though often several courses of treatment were necessary.111
The market leader from the 1970s was Bayer’s ‘Canesten’, the active
principle in which was clotrimazole, developed in its laboratories by
Prof Karl Heinz Büchel and marketed in cream, spray and tablet forms.
It was mainly used for vaginal infection, where it offered excellent symp-
tomatic relief, but it was no cure-all, as the recurrence of infection was
common.112 Initially, ‘Canesten’ was a prescription product, but in the
1990s it became available over the counter. In pessary form, it remained
the market leader for vaginal infection in 2000 and sold well in cream
form for topical infections, including tinea pedis.113
Systemic candidiasis: ‘A disease of the diseased’
The ﬁrst book devoted solely to Candida albicans was published in
1964.114 Its authors were Howard Winner and Rosalinde Hurley, both
of whom worked in clinical pathology at the Charing Cross Hospital,
London.115 Hurley, who qualiﬁed in both medicine and law, went on
to a distinguished career in medical microbiology, always championing
mycology, and eventually working in medical regulation. The authors
saw their book as a response to the increased incidence of the disease
and the burgeoning literature on the topic, yet they were puzzled by the
lack of agreement on many issues.116 One key point of contention was,
had there been a ‘real’ increase in the incidence of C. albicans infec-
tion, or was the increase only apparent and due to greater awareness
and improved diagnostic methods? Winner and Hurley suggested it was
the latter. A key piece of evidence was that reported mortality from
systemic candidiasis (moniliasis had gone out of fashion) showed no
increase at all in recent decades.117 If there had been more infections
in the general population, they argued, there should have been more
deaths in special groups, as there would have been a greater likelihood
of the development of systemic disease. They thought it unlikely that
the availability of nystatin and amphotericin B had changed therapeutic
outcomes in terminal cases. The only change in mortality from fungal
disease since 1940 was the decline in deaths from actinomycosis, which
was susceptible to penicillin.118
A second question was, to what extent was systemic candidiasis a pri-
mary rather than secondary disease? Winner and Hurley went with the
latter, endorsing the old adage that Candida infection was primarily the
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‘local expression of a very bad state of the whole system’, or was ‘a
disease of the diseased’. External infections were associated with pre-
disposing conditions, so it seemed logical that the same applied to
internal disease. Winner and Hurley were quite sceptical of the near
orthodoxy that antibacterial antibiotics were an important predispos-
ing factor to candidiasis and concluded, ‘One is left unable to advance
a precise explanation of the nature of the imbalance between host and
parasite which changes a harmless symbiotic relationship into a disease
which may have lethal consequences.’119 The mortality rate with sys-
temic candidiasis was nearly 90%, which was perhaps unsurprising as
most sufferers had prior serious illnesses.120
The ﬁrst international symposium on Candida infection was held
in London in 1966, supported by the pharmaceutical company
E. R. Squibb & Sons. The proceedings were edited by Winner and Hurley,
and covered all aspects of the infection, but most attention was given
to systemic disease, for which Squibb’s amphotericin B remained the
treatment of choice.121 In the same year, Mildred Seelig, of New York
Medical College, published on ‘The role of antibiotics in Candida infec-
tion.’ She noted that a review of mycotic disease in 1945 by Downing
and Conant had observed that systemic or disseminated infections
with C. albicans were rare.122 Two decades later it was clear things
had changed, for over half of Seelig’s paper was devoted to systemic
disease. The increased incidence was said to be hard to quantify, but
Seelig was in no doubt that there had been a major change. She
argued that this was due ﬁrstly to normally saprophytic organisms
becoming pathogenic; and secondly, to the creation of new groups of
vulnerable patients with altered internal bacterial ﬂora and depressed
immune systems. The former related to the increased use of antibi-
otics, especially combined and broad-spectrum formulations, while the
latter was due to more invasive surgery and new therapeutics, such
as with cortisone.123 One example of the change was candidal endo-
carditis, which was rare in the 1940s, yet by 1961 it was ‘an emerging
peril in cardiovascular surgery’.124 The predisposing factors were: the use
of multiple antibiotics and adrenal corticosteroids; catheterisation and
intravenous ﬂuids; and general poor health of patients.125 The num-
ber of cases associated with cortisone and adrenocorticotropic hormone
(ACTH) was small, but they pointed to a new situation where deep-
seated fungal infections developed as the result of the body’s immuno-
logical and physiological functions deliberately altered by therapeutic
regimes.126 The novelty of such complications in the 1950s meant that
many were written up for publication as rare or atypical cases, giving
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systemic fungal infections a proﬁle that was greater than their clinical
incidence.
The most controversial site for medical debates about the pathogenic-
ity of C. albicans was the lungs, and this went back to tea taster’s cough
in Sri Lanka in the 1920s. Doctors had debated whether C. albicans was
a harmless saprophyte as it was found widely in the sputum of children
and adults, which acted as a reservoir for lung and tracheal infection.127
Bronchopulmonary candidiasis was investigated in the laboratory and
the clinic, with some studies suggesting that fungal infection worsened
asthma and tubercular infection by altering lung tissue and function.128
The number of cases was small, but they were challenging to diagnose
and treat, with suspicions that broncho-mycotic disease was greatly
underreported. Despite there being very few cases, chest physicians
invested some effort in devising criteria to determine whether pri-
mary infection was due to C. albicans. These standards were very tight,
requiring the fulﬁlment of Koch’s postulates to conﬁrm C. albicans and
exclusion of other infections, such as tuberculosis.129
Winner and Hurley’s view of bronchopulmonary candidiasis in 1964
was that nothing had been resolved ‘due to the chronic nature of the
disease, to the fact that histopathological studies are made later in
the course of the illness . . . and that there is no clear-cut association of
a particular clinical and a particular pathological feature at all stages
of the disease’.130 One question was, did it matter whether C. albicans
was the primary or secondary infection? A second was, does this mat-
ter as the treatment would be the same? For many doctors it did matter
and not only to help resolve aetiological uncertainties. They complained
again that there had in fact been an ‘overgrowth’ of laboratory-based
medical mycologists, which had led to fungal infections being over
diagnosed and their clinical signiﬁcance overstated.
Systemic candidiasis gained a higher medical proﬁle in the 1960s and
1970s from its association with immunocompromised patients, either
amongst those with diseases affecting the immune system, principally
leukaemia in the 1960s, and in the growing number of patients on
immunosuppressant therapies, principally anti-inﬂammatory drugs or
anti-rejection drugs in transplant patients in the 1970s. In fact, the
most important anti-rejection drug cyclosporine had been isolated from
a fungus (Tolypocladium inﬂatum) by researchers at the Sandoz Company
in Basel, Switzerland and initially viewed as an antifungal antibiotic.131
However, in the 1980s the numbers of immunocompromised patients
expanded greatly in proﬁle and number with the arrival of HIV/AIDS.
Very early in the epidemic, oral and oesophageal candidiasis were
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reported as opportunistic infections in AIDS sufferers; indeed, it was
considered, along with Kaposi’s sarcoma and pneumocystis pneumo-
nia, as a marker of the disease.132 By the mid-1980s, some estimates
were that 75% of AIDS patients had oral candidiasis and doctors were
recommending that any patient presenting with oral Candida infection
in a high risk group should be screened for the infection.133 From the
early 1990s, when doctors differentiated between those who had AIDS
related complex (ARC), – an early phase of the infection, and those with
AIDS, the respective ﬁgures for Candida infection were 33% and 90%,
respectively.134
From the early 1980s, doctors used nystatin and amphotericin B for
oral thrush in AIDS patients, but the new azoles seemed to hold more
promise.135 They proved effective for the oral and oesophageal forms of
candidiasis common in AIDS patients, though results for systemic dis-
ease were mixed.136 However, another azole, ﬂuconazole, came along in
the mid-1980s. This drug, developed by Pﬁzer as ‘UK-49,858’ in their
laboratories at Sandwich in Kent, was trialled as a superior alternative to
ketoconazole, especially for all forms of candidiasis.137 In 1989, de Wit
and colleagues at the St Pierre University Hospital, Brussels, published
the ﬁrst trial comparing the new drug with ketoconazole in the treat-
ment of oropharyngeal candidiasis in patients with AIDS and ARC.138
They reported that ﬂuconazole was not only more effective, but was
less toxic and better tolerated.139 However, it was unavailable in the
United States and when the ‘People with AIDS Health Group’ heard of
the potential of the drug, it acted as a buyer’s club for patients. The
Group announced that it would import the drug pending US approval,
which was on an accelerated track, though not ﬁnally sanctioned by the
FDA until January 1990.140 Doctors added ﬂuconazole to the range of
drugs used, but treatment regimes varied greatly depending on the type
of infection, likely patient compliance and cost. In addition, drugs were
chosen in relation to the other fungal infections affecting AIDS patients,
such as cryptococcosis, histoplasmosis and coccidioidomycosis.141
Candidiasis in AIDS patients, though common, was reasonably well
controlled with azoles, along with better-tolerated forms of ampho-
tericin B. Reported mortality from candidiasis peaked in HIV/AIDS
sufferers in the mid-1990s, having done so in all patients in 1989.142
What these trends meant was disputed. Frank Odds argued that the
reported mortality for candidiasis was likely to be quite unreliable
because it was not notiﬁable and diagnosis was variable. From close anal-
ysis of the available data for the United States, England and Wales, he
concluded that while it was likely that there had been a ‘real’ increase in
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candidiasis mortality over the 1970s and 1980s, this had probably been
‘exaggerated by a rise in enthusiasm for the study of candidosis [Odds
preferred this term] and improved methods of diagnosis’.143 However,
he was in no doubt that the clinical incidence of the disease was higher
because of the continuing rise in the numbers of immunocompromised
patients and greater awareness of Candida infection.144
The fact that patients treated for systemic candidiasis were relatively
small in number and typically had multiple disease problems meant
that clinical trials with antifungals had not been of the same rigour as
in other ﬁelds. In 1977, the NIH and National Institute of Allergy and
Infectious Diseases (NIAID) had sought to develop better clinical trials
with systemic fungal infections and convened a group to explore the
matter. They met at Atlanta Airport and submitted a bid, led by William
Dismukes, at University of Alabama School of Medicine in Birmingham
for NIH funding.145 The other members of the group were John Ben-
nett (NIH), Gerald Medoff (St. Louis), Richard Duma (Virginia), Merle
Sande (Virginia) and Harry Gallis (Charlotte) and they became known
as the Mycoses Study Group (MSG). The MSG was awarded their ﬁrst
contract by NIAID in the following year and others followed for 27
years. This support allowed the establishment of ‘a Central Adminis-
trative Core Unit based at the University of Alabama School of Medicine
at Birmingham, a Central Biostatistics Unit, distinctly focused disease or
population at-risk study groups with designated principal investigators,
an annual meeting, and partial funding for various types of clinical tri-
als or epidemiologic studies’.146 The ﬁrst trial, comparing amphotericin
B alone and combined with ﬂucytosine in the treatment of cryptococcal
meningitis, was funded by NIAID and the John A. Hartford Foundation,
and published in the New England Journal of Medicine in July 1979.147
A year later they published guidelines for clinical trials with antifungal
drugs and many other studies followed.148
A new problem in the ﬁnal decades of the twentieth century was
candidaemia – C. albicans infection of the blood that was mostly found
as nosocomial infections, that is, those acquired in hospital. The 1979
edition of Frank Odds’s Candida and Candidosis had no chapter on
the condition, but the second edition in 1988 did, driven by the
growing medical and public concern about hospital-acquired Staphylo-
coccus aureus and in particular Methicillin-Resistant Staphylococcus aureus
(MRSA).149 Most nosocomial infection was bacterial, but up to 10% and
rising was due to fungi, with C. albicans the most prevalent; indeed,
mycoses were ranked third or fourth overall. Intensive care units were
important places of infection because of the proliferation of sites where
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C. albicans could either enter the body (e.g. catheters) or grow (mon-
itoring sensors). In some cases, suspected septicaemia, the great dread
of those managing high-dependency patients, was found to be candi-
daemia, which was soon placed amongst a number of systemic blood
infections, termed ‘fungaemia’. A review in 1995 claimed that over
the 1980s the incidence of blood-stream infection due to Candida spp.
increased by almost 500%, though again the question had to be asked,
how much of this was due to greater awareness and better laboratory
testing?150
The requirement for laboratory tests to conﬁrm candidaemia and the
new methods of identifying pathogens revealed that the dominance
of C. albicans as the major cause of candidiasis was under threat from
other species.151 Whereas previously, C. albicans infection had been the
default, the new molecular technologies of identiﬁcation enabled faster
and more accurate differentiation of species. These methods were used
because clinicians needed to monitor the type and number of fungi
due to the emergence of resistance to antifungal drugs. The develop-
ment of resistance had been feared in the 1950s from the overuse of
nystatin and amphotericin B, but this proved less of a problem in
fungi than bacteria because resistance is not readily transmitted between
strains. However, resistance did emerge in the late 1980s, following
from the extensive and intensive use of ﬂuconazole with AIDS patients.
Initially, resistance was partial and overcome by increasing the dose,
though in time other drugs became available, notably posaconazole and
voriconazole. The pattern of drug use also affected the epidemiology
of infective species; for example, use of ﬂuconazole reduced the inci-
dence of C. albicans, but facilitated the increase in C. krusei, which
was resistant to the drug.152 These epidemiological discoveries were
made from case reviews and surveys of the usual suspects: patients with
leukaemia; cancer sufferers and other patients on immunosuppressant
therapies; those in intensive care or high-maintenance therapy, and
those with HIV/AIDS. Moreover, it was of course around this group that
the notion that candidiasis was ‘the disease of the diseased’ gained use
and acceptance.
‘The Yeast Connection’153
Writing in 1988 in the second edition of his book on Candida, Frank
Odds was clear that there had been a ‘public revolution in Candida
consciousness’ in the 1980s.154 However, this was not due to greater
awareness of systemic candidiasis, candidaemia, or infection in those
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with HIV/AIDS, but to two popular books: William Crook’s The Yeast
Connection: A Medical Breakthrough (1982) and Orian Truss’s The Miss-
ing Diagnosis (1983).155 Crook was a paediatrician, who had founded a
Children’s Clinic in the 1950s and served on the staff of the Jackson-
Madison County General Hospital in West Tennessee. He developed an
interest in chronic conditions in children, such as bedwetting, colic,
migraine, fatigue and hyperactivity, coming to favour the idea that
many of these were due to food allergies. He was a populariser, publish-
ing in 1963 a general parenting advice book, Answering parent’s questions,
in the vein of Benjamin Spock, before three books on food allergies
in the 1970s: Your allergic child: a pediatrician’s guide to normal living for
allergic adults and children (1973); Can your child read? Is he hyperactive?
A pediatrician’s suggestions for helping the child with hyperactivity, behavior
and learning problems (1975); and Are you allergic? A guide to normal liv-
ing for allergic adults and children (1978).156 In 1979, Crook claimed that
his life changed – he came across an article by Orian Truss on Candida
infection and chronic diseases in adults in the Journal of Orthomolecular
Psychiatry.157
Orian Truss had a private practice in Birmingham, Alabama and an
interest in allergy and infection.158 He was inﬂuenced by Linus Paul-
ing’s ideas on orthomolecular medicine.159 Pauling had coined the term
in 1968 to refer to ‘the maintenance of health and cure of disease by
regulating the concentration in the body of substances naturally found
there’; this meant, literally, striving to have the ‘right’ chemicals at the
‘right’ levels in the body.160 Pauling pursued this, most famously, in his
support for megavitamin treatments, particularly vitamin C to manage
the common cold, but initially his focus was on psychiatry. The subject
was debated extensively in the early 1970s as dietary management was
an attractive alternative to many of the new neuroleptic drugs and their
side effects, but a report for the American Psychiatric Association in 1973
was highly critical.161 However, orthomolecular medicine enjoyed pop-
ularity as an ‘alternative’ therapy, and, very unusually, one endorsed by
a Nobel Prize winner for Physiology and Medicine.162 Orthomolecular
medicine was one of a number of alternative or fringe medical move-
ments in the 1970s and 1980s that challenged orthodox medicine at
every level and over the nature and treatment of most diseases.163
Orian Truss ﬁrst aired his views on the health effects of yeast aller-
gies and infections at the eighth Scientiﬁc Symposium of Academy of
Orthomolecular Psychiatry in Toronto in May 1977. His talk was pub-
lished in 1979. Truss argued that the persistence of a chronic infection
in the body required ‘the absence of an effective immunologic response
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to the pathogen’ and that in chronic candidiasis, as in leprosy and
tuberculosis, disseminated disease can be due to an ‘antigenic load’ over-
whelming the immune defences.164 In turn, a weakened immune system
would predispose patients to local and general pathological conditions.
He painted a picture of the patient with chronic candidiasis that would
become very familiar in succeeding years; hence, it is worth quoting at
length.
A careful history that traces the illness from its onset suggests the
diagnosis. It invariably includes a story of futile efforts by many com-
petent specialists to establish an organic basis for the chronic illness,
and of the almost irresistible recommendation of psychiatric ther-
apy. Attention in the history should be directed to the inﬂuence of
repeated pregnancies, birth-control pills, antibiotics, and cortisone
and other immunosuppressants. The onset of local symptoms of yeast
infection in relation to the use of these drugs is especially signiﬁ-
cant and usually precedes the systemic response. Repeated courses
of antibiotics and birth-control pills, often punctuated with multiple
pregnancies, lead to ever-increasing symptoms of mucosal infections
in the vagina and gastrointestinal tract. Accompanying these are
manifestations of tissue injury based on immunologic and possibly
toxic responses to yeast products released into the systemic circu-
lation. Many infections are secondary to allergic responses of the
mucous membranes of the respiratory tract, urethra, and bladder,
necessitating increasingly frequent antibiotic therapy that simultane-
ously aggravates and perpetuates the underlying cause of the allergic
membrane that allowed the infection. Depression is common, often
associated with difﬁculty in memory, reasoning and concentration.
These symptoms are especially severe in women, who in addition
have great difﬁculty with the explosive irritability, crying, and loss
of self-conﬁdence that are so characteristic of abnormal function of
the ovarian hormones. Poor end-organ response to these sex hor-
mones is conﬁrmed by the common association of acne, impairment
or total loss of libido, and the whole range of abnormalities of men-
strual bleeding and cramps, as well as a very high incidence of
endometriosis in those who have undergone hysterectomy. Many
of these patients also start developing multiple intolerances to foods
and chemicals, making it increasingly difﬁcult for them to live in a
normal environment. Many or all of these intolerances disappear as
the yeast problem is brought under control.165
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Table 3.1 Treatment of chronic candidiasis166
I. Non-immunologic measures that retard yeast proliferation
A. Passive: measures of avoidance
1. Diet: low in carbohydrates and in foods with high yeast or meld content
2. Antibiotics
3. Contraceptive hormones
4. Environments characterised by high meld-spore exposure
B. Active: therapy with antifungal drugs: nystatin, amphotericin-B, ﬂucytosine,
ketoconazole
II. Measures to strengthen the immune response of the host
A. Passive (avoidance): immunosuppressant drugs
B. Active
1. Diet: adequate nutrients for proper immune response
2. Correction of unrelated conditions that impair the immune response, for
example, hypothyroidism




Truss’s treatments aimed to restore immunological ‘competence’ and, as
seen below in Table 3.1, while his preventive and treatment regimens
recommended avoiding antibiotics and immunosuppressants, they
included the use of antifungal drugs. Therefore, while presenting him-
self to readers as a holistic, alternative practitioner, Truss was a quite
pragmatic in his clinical work and used the full range of orthodox drugs,
including nystatin and the new azoles.
Truss also drew inspiration from the work of Theron G. Randolph,
the ‘father of clinical ecology’ and his idea that a key determinant for
health in modern societies was to avoid exposure to chemical contami-
nants of air and water, including antibiotics.167 Clinical ecologists were
on the fringe of American medicine, as signalled in 1981, when the
California Medical Association (CMA) adopted the position that clini-
cal ecology does not constitute a valid medical discipline. The critique,
widely endorsed by medical organisations, stated that scientiﬁc and clin-
ical evidence does not support the diagnosis of ‘environmental illness’
and ‘cerebral allergy’, and that evidence is lacking for the concept of
massive environmental allergy.168
In the preface of The Yeast Connection, William Crook wrote that he
had read Truss’s paper on C. albicans and chronic illness in the summer
of 1979 and immediately tried the suggested treatment regime on one
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of his difﬁcult patients, ‘a 41-year old woman (I’ll call her Nancy Jones)
with severe chronic hives [urticaria], accompanied by mental confusion,
fatigue and depression’.169 He started her on nystatin and a yeast-free,
low carbohydrate diet. Within six days her hives had improved, in
weeks they disappeared and after almost a year all her symptoms had
improved. Crook reported trying the regimen with another 20 patients.
Nearly all were adults with complex health problems, including
headache, fatigue, depression, recurrent vaginal infection, joint pain
and sensitivity to chemical odours and additives. Almost without
exception, they improved. And some improved dramatically.170
He continued ad hoc variations in his treatments, extending the range
of conditions and ages, eventually to include his paediatric patients. In
the meantime, Truss had been featured in the ‘Dan Freeman Report’ on
CNN in September 1981, an appearance that allegedly brought more
responses than any previous programme.
In was not long before Truss and Crook joined forces and they did
so ﬁrst at an ‘informal’ conference they called on ‘C. albicans and the
relationship to human disease’ in Dallas, Texas, in July 1982.171 This was
attended by 20 physicians and an equal number of patients. Crook made
his television debut on the subject in Cincinnati in January 1983, in a
broadcast that led to 7,300 requests for more information and his deci-
sion to write The Yeast Connection. In the meantime, Truss self-published
The Missing Diagnosis; but it was Crook and his book that gained the
public’s attention, not least because he was accessible to the media and
an effective communicator. The ﬁrst print run of The Yeast Connection in
1983 quickly sold out. He claimed that 270,000 copies were purchased
in the ﬁrst two years. Crook wrote in the preface that, already, ‘my recog-
nition of “the yeast connection” has changed my life and my practice
and had enabled me to help many, many patients conquer previously
disabling illnesses’. The book was in its fourth edition in 1986.
Crook soon had wider ambitions, hoping to forge what he saw as ‘The
Coming Revolution in Medicine’.172 He had written The Yeast Connection
as a self-help manual, with checklists, diagrams, illustrations and clear
preventive and therapeutic advice on necessary changes in lifestyle and
diet, including recipes, and special measures for different patient groups.
One of the most controversial features of the book was its 10-point
self-diagnosis schedule, where three or four ‘yes’ answers suggested that
‘yeasts played a role in your symptoms’.173 The explanation of the causes
of yeast overgrowth was presented in words and graphics. Crook’s advice
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was threefold: ﬁrst, ‘avoid foods which promote yeast growth’; second,
seek a prescription from your doctor for ‘medication which helps rid
your body of yeast germs’ (nystatin or ketoconazole); and, third, make
changes to your lifestyle and behaviour. In the early 1980s, taking pre-
scription antifungal drugs was an integral part of the treatment and the
merits of nystatin and ketoconazole were discussed in some detail.174
However, later and in the hands of other advocates, the self-help and
‘alternative’ features took over, as the regime moved to a natural therapy,
not least because many doctors refused patients antifungal drugs as they
did not accept that ‘fungal overgrowth’ was a disease or syndrome at all.
The popular success of Truss and Crook brought imitators who linked
Candida overgrowth directly to other, so-called, ‘twentieth century
diseases’.175 In the hands of Truss and Crook, ‘fungal overgrowth’ had
always been linked to allergies and infection, and to chemical sensi-
tivities, hyperactivity and mental disorders.176 Soon the illnesses they
had identiﬁed were medicalised by other doctors, with such names as
the Candida syndrome, Candida allergy syndrome, the yeast syndrome,
polysystemic chronic candidiasis, chronic candidiasis syndrome and,
most commonly, candidiasis hypersensitivity syndrome (CHS). In June
1984, Crook branched out from popular writing and appearances to
advance ‘The Yeast Connection’ to the American medical profession.
His chosen subject was depression and he wrote a letter to the Journal
of the American Medical Association suggesting that the condition was
‘commonly related to prolonged or repeated courses of broad-spectrum
antibiotics or to birth control pills, which promote the overgrowth
of C. albicans on mucous membranes’.177 He acknowledged that the
‘mechanisms involved still have not been clearly elucidated’, but wrote
that he had good evidence ‘from clinical history, followed by a ther-
apeutic response to oral nystatin and a yeast-free, low-carbohydrate
diet’. His views were rounded upon by several correspondents, who
dismissed his claims as lacking evidence and being based on multiple
misconceptions.178
The following year, several medical organisations attacked Crook,
Truss and their followers. The American Academy of Allergy and
Immunology was worried by the attention being given to CHS and
in August 1986 published a position statement in its journal.179 The
Practice Standards Committee found ‘multiple problems with the can-
didiasis hypersensitivity syndrome’; principally that ‘the concept is
speculative and unproven’ and that ‘elements of the proposed treat-
ment program are potentially dangerous’. The Committee stated that
‘basic elements of the syndrome would apply to almost all sick patients
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at some time’ and that ‘the broad treatment program would produce
remission in most illnesses regardless of cause.’ Moreover, there was ‘no
published proof that C. albicans is responsible for the syndrome’ or that
‘treatment . . .with speciﬁc antifungal agents . . .beneﬁts the syndrome.’
The dangers in the treatment regimes were that the promiscuous use of
drugs would produce resistant strains of C. albicans and of that there
could be long-term effects with patients on systemic antifungals for
many years. In November 1987, at a meeting on Controversies in Infec-
tious Disease, John E. Edwards of (UCLA) attacked Crook and those on
his bandwagon.180 His description nicely captured the frustrations of
regular medicine.
Certain generalizations can be made regarding ‘the yeast connec-
tion.’ The symptoms described by the authors are generalized and
affect nearly every organ system. As listed, some symptoms are widely
diverse; for instance, both fatigue and hyperactivity are included.
Nearly every normal individual has had certain of these symptoms
during the course of a normal lifespan. Case reports are anecdotal.
Possibly none of the authors have had formal training in the disci-
plines of allergy and immunology, infectious diseases, or mycology.
After nearly a decade since the original description, no articles on
this disease appear in peer reviewed journals included in the Index
Medicus. There are no prospective controlled therapeutic studies, and
there are no animal model data.181
A year later, the Canadian Paediatric Society warned that, ‘Physicians
must not be swayed by the attention that the syndrome has attracted in
the lay press.’182
The Yeast Connection was published in Britain in the summer of 1988.
Chronic candidiasis had been discussed in the popular press for a cou-
ple of years and linked to myalgic encephalomyelitis (ME) or post-viral
fatigue syndrome (PVFS).183 In The Observer, Sue Finlay wrote that ME
was ‘An illness doctors don’t recognise’, but which she had overcome
by following the diet recommended in Leon Chaitow’s Candida albi-
cans: Could Yeast Be Your Problem?184 Clinical ecologists also gained a
hearing in Britain. One described Candida overgrowth as ‘the quiet epi-
demic that is ruining modern lifestyles’, due to the speciﬁc condition of
‘dysbiosis [abnormal intestinal ﬂora]’ and to ‘[t]he burgeoning of com-
plex viral infections such as AIDS and ME – and, to a lesser extent,
Herpes’.185 In these conditions, it was claimed, ‘candidiasis was almost
always present as an immune-sapping illness’.
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Although there was a pathological theory behind The Yeast Connection,
Crook relied on the claim that the real test of his ideas and recommenda-
tions was in the clinic. He once said, ‘There’s not a single test to prove it,
but it works’ and used emotive case histories to great effect; such as that
of Darlene Lindbom of Paris, Tennessee, who ‘went to two universities
in a wheelchair. “You’ve got something like MS”, they told her – she had
spinal taps, biopsies, the lot. I put her on my special diet and nystatin.
Now she’s ﬁt and runs a successful business.’186 Crook visited London to
promote his ideas in June 1988, which the Guardian styled the ‘thrush
theory’. He stressed the link to food allergies and found a forum with the
British Society for Allergy and Environmental Medicine, which had links
with the British Society for Nutritional Medicine.187 Both meetings were
regarded as ‘alternative’ by the mainstream British medical profession
and studiously ignored.
In 1989 the ﬁrst clinical trials with patients reporting the ‘Yeast Con-
nection’ were published. Lisa Renfro and colleagues at the Department
of Pediatrics and Family Medicine at Farmington, Connecticut, reported
on 100 consecutive patients suffering from chronic fatigue, eight of
whom believed their symptoms were due to chronic candidiasis.188 The
article concluded that the authors were ‘unable to ﬁnd physical or lab-
oratory ﬁndings that were different from the 92 other patients with
chronic fatigue’. However, they did ﬁnd that ‘patients with the yeast
connection were more likely to be taking high doses of vitamins and
were more likely to be getting help from non-medical caretakers. In fact,
these caretakers might be the source of the diagnosis.’189 They went on
to conclude that all but one sufferer had depression or an anxiety disor-
der, and that, from the point of view of achieving a positive outcome,
not dismissing chronic candidiasis might be beneﬁcial in allowing a
therapeutic relationship between doctor and patient to be maintained.
The following year a similar study was published by doctors at the
University of Alabama Medical School in Birmingham, Crook’s local
stomping ground.190 This was a state-of-the-art randomised, double-
blind trial of nystatin therapy in CHS, which concluded that, while
patients on the trial improved, as was to be expected, the study had pro-
vided ‘additional objective evidence that the syndrome is not a veriﬁable
condition’.191 An accompanying editorial in the New England Journal of
Medicine anticipated that supporters of the yeast connection would not
be impressed and, as expected, Crook and others wrote in pointing to
successful treatment in with many patients.192
In Britain, the yeast connection only attracted sustained medical
criticism in the early 1990s and then in the context of a complex
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debate that linked allergies, food intolerance and alternative medicine.
These issues crystallised in a report by the Royal College of Physi-
cians on Allergy: Conventional and Alternative Concepts, in 1992, which
stated the ‘Candida theory is unsubstantiated’.193 Responses quickly
appeared in ‘alternative’ medical publications, particularly in the Jour-
nal of Nutritional Medicine; however, the speciﬁcs of the ‘Candida theory’
were lost in a larger dispute on the status of ‘alternative’ medicine.194
In July 1992, Keith Mumby, Britain’s most high-proﬁle clinical ecolo-
gist, appeared before the General Medical Council (GMC) and was found
guilty of ‘touting for charges’ and failing to give a patient adequate med-
ical attention.195 This led the main author of the College’s Report on
Allergy, Barry Kay, to argue that the ‘GMC should consider censoring
all forms of diagnosis and treatment which, by reasonable standards,
have consistently failed to show clinical efﬁcacy’. Mumby was allowed
to reply in an article entitled ‘Science or ﬂat earthers? The clinical ecol-
ogist replies’.196 This was almost the last word, as the stridency and
frequency of the medical establishment’s assault of alternative practi-
tioners waned, though patient demand in Britain and the United States
continued to grow.197 In medicine, CHS was gradually absorbed into a
number of, what became known as, ‘symptom-based conditions’, which
included chronic fatigue syndrome, ﬁbromyalgia, multiple chemical
sensitivities, sick building syndrome, Gulf War syndrome and irritable
bowel syndrome.198 Crook continued to publish, seeking niche markets
with cook books and patient-speciﬁc audiences: women, children with,
attention deﬁcit disorder and autism, and people with chronic fatigue
syndrome.199 Many other authors expanded the genre, with titles such
as The Candida Control Cookbook (1996), Feast Without Yeast: 4 stages to
better health (1999), and Complete Candida Yeast Guidebook: everything you
need to know about prevention, treatment, & diet (2000). However, the med-
ical profession increasingly ignored CHS, except to dismiss it, especially
because of the new emphasis on evidence-based medicine and the Gold
Standard of double blind controlled clinical trials.200
Antibiotics were the icon of mid-twentieth-century medical progress
and their development inﬂuenced Candida infection in complex ways.
As thrush, the disease came to the fore in the post-war years when
nystatin, the ﬁrst antifungal antibiotic, was introduced and brought
women with the vaginal infection to the clinic. Doctors believed that
previously the condition had been self-treated or accepted, perhaps self-
limiting, but had certainly been underreported. At the same time, the
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use of antibacterial antibiotics, especially broad-spectrum formulations,
by clearing the body of its natural microbial fauna, seemed to open the
body to topical infection. New clothing may have been a factor too,
with stretch synthetic fabrics making underwear more close ﬁtting and
impermeable. Antibiotics were also implicated in systemic or invasive
candidiasis, as the numbers of vulnerable patients multiplied. Amongst
cancer patients, steroid and other treatments depressed the immune sys-
tem, as did blood cancers like leukaemia. Some of the new systemic
candidiasis patients suffered from iatrogenic conditions. The principal
groups were transplant patients, those in intensive care, those main-
tained with serious chronic conditions and then people with HIV/AIDS.
However, the rising tide of candidiasis was met with new antifungal
antibiotics, especially azole drugs and, by the 1990s the management
of systemic candidiasis was more successful. In the 1980s another new
type of candidiasis emerged, CHS, which although dismissed by main-
stream medicine as a ﬁction and a fad, became the archetypal ‘disease
of modernity’. Its alleged cause, overgrowth of C. albicans in the body,
was linked to many features of modern life, including the overuse of
antibiotics. It was not without irony, therefore, that, alongside lifestyle
and dietary changes, taking the antifungal antibiotics produced by the
modern pharmaceutical industry was also recommended.
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